Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1235-1243

  Faião Flores, Fernanda ^a,b   Suarez, José Agustín Quincoces ^c   Soto Cerrato, Vanessa ^d   Espona Fiedler, Margarita ^d   Pérez Tomás, Ricardo ^d   Maria, Durvanei Augusto ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Universidade Bandeirante de Sao Paulo   (Brazil)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; Bcl 2 proteins; Cell adhesion; Curcumin analog; DM 1; Melanoma

Indexed keywords

CASPASE 3; CASPASE 9; CURCUMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SODIUM 4 [5 (4 HYDROXY 3 METHOXYPHENYL) 3 OXO PENTA 1,4 DIENYL] 2 METHOXY PHENOLATE; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; DRUG DERIVATIVE; EMTANSINE; MAYTANSINE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL X;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DETACHMENT; CELL LEVEL; CELL STRAIN A375; CELL STRAIN SK MEL 5; CELL STRUCTURE; CELLULAR PARAMETERS; CYTOSKELETON; DOWN REGULATION; DRUG CYTOTOXICITY; FILOPODIUM; FOCAL ADHESION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MELANOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPICULE FORMATION; CELL PROLIFERATION; DRUG EFFECT; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOSKELETON; HUMANS; MAYTANSINE; MELANOMA; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84877155651     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0666-6     Document Type: Article

References (52)

1. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol. 2012;23:10-4.
2. Marsden JR, Newton-Bishop JA, Burrows L. Revised UK guidelines for management of cutaneous melanoma. Br J Dermatol. 2010;163:238-56.
3. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-51.
4. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-66.
5. Lillehammer T, Engesaeter BO, Prasmickaite L, et al. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med. 2007;9:440-51.
6. Carvalho FR, Vassão RC, Nicoletti MA, et al. Effect of Curcuma zedoaria crude extract against tumor progression and immunomodulation. J Venom Anim Toxins Incl Trop Dis. 2010;16:324-41.
7. Abusnina A, Keravis T, Yougbaré I, et al. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res. 2011;55:1677-89.
8. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int. 2009;29:1457-66.
9. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol. 2009;6:192-9.
10. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353-6.
11. Faião-Flores F, Pardi PC, Santos RP, et al. Antiproliferative and antimetastatic activity of DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo- penta-1,4-dienyl]-2-methoxy-phenolate, in B16F10 melanoma. Appl Cancer Res. 2008;28:72-9.
12. Faião-Flores F, Suarez JA, Pardi PC, et al. DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment. Tumour Biol. 2012;33:775-85.
13. Faião-Flores F, Quincoces Suarez JA, Stuchi-Engler SM, et al. The curcumin analog DM-1 induces apoptotic cell death in melanoma. Tumor Biol. 2013. doi: 10.1007/s13277-013-0653-y.
14. Gilmore AP. Anoikis. Cell Death Differ. 2005;12:1473-7.
15. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856-9.
16. Green DR. Apoptotic pathways: ten minutes to dead. Cell. 2005;21:671-4.
17. Quincoces Suarez JA, Rando DG, Maria DA, et al. Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives and derivatives with antitumoral and antiparasitic properties, the compounds and their uses. Brazilian Patent PI 0602640-0 (06.07.2006); PCT/BR2007/000175 (06.07.2007); WO 2008/003155.
18. Quincoces Suarez JA, Maria DA, Faião-Flores F, et al. Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in human and animals. Brazilian Patent: PI 0902039-0; 09/06/2009; PCTBR2009/000375; 11.11.2009; WO 2010/142007; 16/12/2010.
19. Quincoces Suarez JA, Rando DG, Santos RP, et al. New antitumoral agents I: in vitro anticancer activity and in vivo acute toxicity of synthetic 1,5-bis(4-hydroxy- 3-methoxyphenyl)-1,4-pentadien-3-one and derivatives. Bioorg Med Chem. 2010;18:6275-81.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
21. Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9:446-54.
22. Ma Y, Halade GV, Lindsey ML. Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res. 2012. doi: 10.1007/s12265-012-9398-z.
23. Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-β function. J Biochem. 2012;152:321-9.
24. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84:345-57.
25. Burridge K, Fath K, Kelly T, et al. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 1988;4:487-525.
26. Meredith JE, Schwartz MA. Integrins, adhesion and apoptosis. Trends Cell Biol. 1997;7:146-50.
27. Chen CS, Mrksich M, Huang S, et al. Geometric control of cell life and death. Science. 1997;276:1425-8.
28. Frisch SM, Ruoslahti E, et al. Integrins and anoikis. Curr Opin Cell Biol. 1997;9:701-6.
29. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest. 2001;107:785-90.
30. Shi Q, Wada K, Ohkoshi E, et al. Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens. Bioorg Med Chem. 2012;20:4020-31.
31. Wang Y, Chen Z, Xiao L, et al. Evaluating cell migration in vitro by the method based on cell patterning within microfluidic channels. Electrophoresis. 2012;33:773-9.
32. Wehrle-Haller B. Structure and function of focal adhesions. Curr Opin Cell Biol. 2012;24:116-24.
33. Romero S, Quatela A, Bornschlögl T, et al. Filopodium retraction is controlled by adhesion to its tip. J Cell Sci. 2012. doi: 10.1242/jcs.104778.
34. Banerji A, Chakrabarti J, Mitra A, et al. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett. 2004;211:235-42.
35. Soung YH, Chung J. Curcumin inhibition of the functional interaction between integrin α6β4 and the epidermal growth factor receptor. Mol Cancer Ther. 2011;10:883-91.
36. Shimazu T, Degenhardt K, Kamal AN, et al. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev. 2007;21:929-41.
37. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294-305.
38. Pearce AF, Lyles DS. Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL. J Virol. 2009;83:9102-12.
39. Gillissen B, Wendt J, Richter A, et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biochem. 2010;188:851-62.
40. Wang YF, Jiang CC, Kiejda KA, et al. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res. 2007;13:4934-42.
41. Du X, Youle RJ, FitzGerald DJ, et al. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cel Biol. 2010;30:3444-52.
42. Bill MA, Bakan C, Benson Jr DM, et al. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther. 2009;8:2726-35.
43. Kunwar A, Jayakumar S, Srivastava AK, et al. Dimethoxycurcumin-induced cell death in human breast carcinoma MCF7 cells: evidence for pro-oxidant activity, mitochondrial dysfunction, and apoptosis. Arch Toxicol. 2012;86:603-14.
44. Emam H, Zhao QL, Furusawa Y, et al. Apoptotic cell death by the novel natural compound, cinobufotalin. Chem Biol Interact. 2012;199:154-60.
45. Wu S, Zhu H, Gu J, et al. Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3- dichlorophenoxy)propyl]amino] ethanol. Cancer Res. 2004;64:1110-3.
46. Kanwar SS, Yu Y, Nautiyal J, et al. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res. 2011;28:827-38.
47. Fossey SL, Bear MD, Lin J, et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer. 2011;11:112.
48. American Type Culture Collection, 2012. A375 CRL-1619™. Available: http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default. aspx?ATCCNum=CRL-1619&Template=cellBiology. Accessed 29 august 2012.
49. American Type Culture Collection, 2012. SK-MEL-5 #HTB-70™. Available: http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/ 452/Default.aspx?ATCCNum=HTB-70&Template=cellBiology. Accessed 29 august 2012.
50. Min FL, Zhang H, Li WJ, et al. Effect of exogenous wild-type p53 on melanoma cell death pathways induced by irradiation at different linear energy transfer. In Vitro Cell Dev Biol Anim. 2005;41:284-8.
51. Girnita L, Girnita A, Brodin B, et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 2000;60:5278-83.
52. Placzek WJ, Wei J, Kitada S, et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2010;1:e40. Estado de São Paulo Estado de São Paulo